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Introduction
Despite improvements in the modalities for early diagno-
sis of esophageal cancer, the majority of patients still tend 
to have widespread disease at the time of diagnosis [1]. 
Locally advanced esophageal carcinomas are treated with 
current modalities for early diagnosis and perioperative 
multimodalities. Although morbidity and mortality rates 
after surgical treatment for advanced esophageal cancer 
have decreased, the 5-year survival rate after curative sur-
gery is still only 20–36 % [2]. In patients with operable 
esophageal cancer, there is evidence supporting the use of 
preoperative chemotherapy [3, 4], but optimal chemother-
apy for this disease has not been defined.
Patients with obvious T4 (non-resectable) or inoperable 
disease are usually treated with various chemotherapy strat-
egies or chemoradiotherapy. However, their survival is still 
not satisfactory [5–8]. The most frequently used chemo-
therapy regimen for patients with metastatic disease is a 
combination of 5-fluorouracil (5-Fu) and cisplatin (CDDP), 
with response rates ranging from 15 to 45 % [9].
Meanwhile, many chemotherapy regimens for locally 
advanced tumors have been reported to date. Despite the 
availability of various chemotherapy regimens, advanced 
esophageal cancer carries a very poor prognosis, with a 
mean survival time of less than 8.1 months with current 
chemotherapies used singly or in combination with 5-FU, 
vindesine, mitomycin, docetaxel (TXT), paclitaxel, CDDP, 
irinotecan, vinorelbine, or capecitabine [10]. Fluorouracil 
and CDDP combination therapy (FP) is regarded as stand-
ard [11], for which the median survival time is reported 
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to be 9.2 months for responders and 5.3 months for non-
responders [12]. The response rates reported with FP 
range from 35 to 40 %, whereas the 2-year survival rates 
of patients with locally advanced esophageal cancer range 
from 8 to 55 %, with a mean of 27 % [13–15].
The next generation of regimens to treat both distant 
metastasis and locally advanced cancer has begun to be 
developed. Many studies have shown that the taxanes have 
significant activity in patients with locally advanced and 
metastatic esophageal carcinomas [16–20].
The combination of TXT, CDDP, and 5-FU (DCF) has 
shown activity in upper gastrointestinal malignancies with 
different mechanisms. In Europe, DCF combination therapy 
is commonly used in patients with advanced gastric cancer. In 
a report from the V325 study group, patients with advanced 
gastric or gastroesophageal junction cancer receiving DCF 
not only had statistically improved overall survival and time-
to-tumor progression, but they also had better preservation of 
quality of life compared with patients receiving FP therapy 
[21]. Advanced esophageal cancer might also benefit from 
the possibility of such a triple-combination regimen.
It is now necessary to reduce both the hematological and 
non-hematological toxicities as much as possible. Chemo-
therapy can significantly improve the clinical outcomes of 
cancer patients, but it can also cause serious adverse effects 
[22]. Treatment with DCF in esophageal cancer is reported 
to be associated with increased response rates but also with 
a highly increased incidence of toxicities, the most common 
of which are hematological and gastrointestinal [23, 24]. 
Thus, there is an urgent need for the creation of more effec-
tive treatment regimens with fewer adverse events. We there-
fore previously conducted a phase I clinical trial of DCF in 
patients with advanced thoracic esophageal squamous cell 
carcinoma (SCC) with T3–4 tumors and/or M1 staging with 
divided administration of each drug into two blocks per 
one course, i.e., biweekly DCF (Bi-DCF). We determined 
the recommended dose for use in phase II trials to be TXT 
35 mg/m2, CDDP 40 mg/m2, and 5-Fu 400 mg/m, as was 
already reported [22]. In particular, preoperative chemother-
apy for advanced esophageal carcinoma requires tolerability, 
because subsequent radical surgery for esophageal cancer is 
invasive for patients. We then carried out a phase II single-
center study of preoperative chemotherapy with Bi-DCF in 
patients with clinical stage II/III thoracic esophageal SCC.
Patients and methods
Patient eligibility criteria
To be eligible for the study, patients had to be at least 
18 years of age at the time of enrollment and have histolog-
ically or cytologically confirmed SCC, which was a locally 
advanced clinical stage II/III (International Union Against 
Cancer TNM classification system, 7th edition [25]). They 
also had to have an Eastern Cooperative Oncology Group 
(ECOG) performance status of 0–1, a life expectancy of 
>12 weeks, and adequate liver, bone marrow, renal, and 
cardiovascular function as indicated by a serum bilirubin 
≤1.5 mg/dl, neutrophil count ≥1500/mm3, serum aspar-
tate aminotransferase and alanine aminotransferase ≤twice 
the upper limit of normal range, platelet count ≥10 × 104/
mm3, hemoglobin ≥8.0 g/dl, and creatinine ≤1.2 mg/
dl (or creatinine clearance >60 ml/min). Patients previ-
ously treated with chemotherapy for disease or irradiation 
to major bone areas were excluded from the study. The 
major exclusion criteria included serious concomitant ill-
ness, symptomatic infectious disease, severe drug allergy, 
symptomatic peripheral neuropathy, or uncontrolled diabe-
tes mellitus.
Study approval
All participants had to sign an informed consent form 
approved by the Ethical Committee of Gifu University 
Hospital before study entry.
Treatment plan
Chemotherapy
Patients received TXT diluted in 250 ml of normal saline at 
a dose of 35 mg/m2, which was infused intravenously (iv) 
over 2 h, followed by a maintenance infusion given for the 
next 2 h. Then, CDDP was prepared in normal saline at a 
dose of 40 mg/m2 and administered iv over 2 h on day 1. 
5-FU was prepared in normal saline at a dose of 400 mg/
m2 and administered iv continuously on days 1–5. TXT and 
CDDP were given on days 1 and 15, and 5-FU was given 
on days 1–5 and 15–19 of every 28-day cycle (one course). 
All patients were premedicated with granisetron 2 mg iv. 
Hypersensitivity reactions were treated with prophylactic 
use of dexamethasone 8 mg iv, which was infused 1 h prior 
to the administration of TXT. Further, dexamethasone was 
prescribed at a dose of 4 mg orally for 2 days after admin-
istration of the TXT to reduce the risk of hypersensitivity 
reaction and fluid retention. Diuretics were added at the 
discretion of the treating physician. Appropriate hydration 
was given before and after the CDDP infusion. Antiemet-
ics were recommended on subsequent days as needed. The 
protocol did not allow the use of prophylactic granulocyte 
colony-stimulating factor (G-CSF) and antimicrobial ther-
apy during chemotherapy. Patients were treated with hospi-
talization at first course. As long as serious adverse events 
did not occurred, all patients discharged at second course 
except days of drug administration.
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Treatment assessment and dose modifications
All patients underwent complete staging procedures to doc-
ument disease extent, including ECOG performance status, 
medical history, and physical examination. Clinicopatho-
logical factors were analyzed based on the TNM classifica-
tion [25].
Prestudy laboratory evaluation, including a complete 
blood cell count, serum electrolytes, urea, creatinine and 
24-h creatinine clearance, bilirubin, alkaline phosphatase 
and transaminases, CEA, SCC, CA19-9, and CYFRA 
measurements, and electrocardiogram were obtained within 
1 week before initiation of treatment and at the start of each 
treatment cycle. Baseline computed tomography (CT) or 
magnetic resonance imaging (MRI) scans were performed 
within 4 weeks prior to study entry. All patients had a com-
plete blood count taken every week during chemotherapy. 
Levels of electrolytes, serum creatinine, transaminases, 
alkaline phosphatase and bilirubin, and plasma urea were 
measured every week until receiving surgery.
Toxicity was graded every week during the study 
according to the US National Cancer Institute—Common 
Terminology Criteria for Adverse Events (NCI-CTC) ver-
sion 4.0 [26].
Measurable lesions except for the primary tumor were 
evaluated by CT or MRI and assessed according to the 
Response Evaluation Criteria in Solid Tumors (RECIST) 
[27]. A complete response was defined as complete dis-
appearance of all clinically detectable malignant disease. 
A partial response was defined as a ≥30 % decrease in 
the sum of the perpendicular diameters of all measurable 
lesions lasting at least 4 weeks. Progressive disease was 
defined as a ≥20 % increase in the sum of the products of 
measurable lesions over the smallest sum observed, or the 
appearance of new lesions. Stable disease did not qualify 
as complete response, partial response, or progressive dis-
ease. Close follow-up was made from both endoscopy and 
radiographic films or scans taken to document treatment 
response during therapy and was repeated in the 4th week 
of every course of treatment and 4 weeks after completion 
of the 2 courses or sooner if the patient appeared to show 
disease progression.
Response rate (complete or partial) was confirmed 
4 weeks after completion of the 2 courses of chemo-
therapy. Then, patients received right thoracotomy with 
thoracic esophagectomy within 14 days. A thoracoscopic 
surgery was permitted. If disease progression or new 
metastasis was detected after 1 course, the subsequent 
cycle was not permitted, and immediate surgery or chemo-
radiation was mandated. Regional lymphadenectomy con-
sisted of two- or three-field extended lymphadenectomy. 
Evaluations of residual tumor (R) were classified as fol-
lows: R0, no residual tumor; R1, suspicious of residual 
tumor or microscopic residual tumor; or R2, macroscopic 
residual tumor.
After surgery, the primary tumor was examined for his-
topathological changes using a grading system by the Japa-
nese Classification of Esophageal Carcinoma [28], with the 
following grades: grade 3 (markedly effective; no viable 
cancer cells; pathologically complete response), grade 2 
(moderately effective; viable cancer cells account for less 
than 1/3 of tumor tissue, whereas other cancer cells show 
severe degeneration or necrosis), and grade 1 (slightly 
effective, where apparently viable cancer cells account for 
1/3 or more of the tumor tissue, but there is some evidence 
of degeneration of cancer tissue or cells). Grade 1 lesions 
were also subclassified into grade 1a (viable cancer cells 
account for ≥2/3 of tumor tissue), grade 1b (viable can-
cer cells account for ≥1/3, but <2/3, of tumor tissue), and 
grade 0 (ineffective, denoting no discernible therapeutic 
effect on cancer tissue or cells).
Dose adjustment was carried out by reducing the doses 
of TXT, CDDP, and 5-Fu by 20 % in the subsequent course 
if grade 4 hematological toxicity or grade 3 or 4 non-hema-
tological toxicity was present. If there was no improvement 
in grade 3/4 toxicity on the day of predetermined course, 
we postponed the chemotherapy.
We terminated the protocol treatment if serious adverse 
reactions were manifested, clear progression of the dis-
ease was observed, or the physician otherwise judged that 
administration should be stopped.
Endpoints and statistical methods
The primary objectives of this phase II study was the com-
pliance with treatment completion. Patients were con-
sidered to have completed treatment if they received 2 
courses of chemotherapy and pathologically proven com-
plete resection (R0). Secondary objectives included: the 
safety and tolerability of this chemotherapy; evaluation of 
operative morbidity and mortality; and evaluation of effi-
cacy including response rate, pathological response, 1-year 
relapse-free survival (RFS), and overall survival (OS).
In this phase II trial, we expected that the clinical inci-
dence of toxicities with Bi-DCF would increase above 
that with FP in the preoperative design, and that the rate 
of treatment completion would be lower than that in 
JCOG 9907 (89.6 %) [29]. Accordingly, we assumed a 
null hypothesis with a 75 % completion rate for protocol 
treatment and expected a completion rate of protocol treat-
ment of 90 %. Given a one-sided alpha of 0.1 and statisti-
cal power of 80 %, a minimum of 28 patients was needed. 
Assuming a dropout rate of 10 %, the projected sample size 
was 32 patients in total.
Relapse-free survival was defined as the time from the 
date of registration to the first documentation of disease 
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recurrence. Overall survival was measured from the date of 
registration to the date of the last follow-up or death. Sta-
tistical data were obtained using the SPSS 20.0 software 
package (SPSS Inc., Chicago, IL, USA).
This trial was registered with the University Hospital 
Medical Information Network (No. UMIN 000014625).
Results
Patient characteristics
Between January 2010 and September 2014, 32 patients 
were enrolled into the study. Demographic and clinical 
characteristics of the study population are summarized in 
Table 1. All patients had locally advanced esophageal SCC. 
The median patient age was 68 years (range 40–75 years). 
All patients had an ECOG performance status of 0–1. 
Finally, 32 patients were enrolled, and all patients fully 
underwent Bi-DCF therapy.
Toxicity
Overall toxicities during chemotherapy are listed in 
Table 2. The major toxicities were leukopenia and neu-
tropenia. Two patients (6.3 %) had grade 4 and 8 patients 
(25 %) had grade 3 neutropenia; however, no patients had 
febrile neutropenia. Two patient with grade 4 neutrope-
nia received G-CSF. Common non-hematological adverse 
events were anorexia, fatigue, mucositis, diarrhea, and 
alopecia. No grade 3 or 4 hyponatremia was occurred. All 
events were below grade 2. No treatment-related deaths 
occurred. All toxicities were within expectations and were 
manageable.
Surgery and postoperative complications
All patients received surgery as listed in Table 3. Subtotal 
esophagectomy via right thoracotomy with two- or three-
field lymphadenectomy was performed in 30 patients. 
Two patients received subtotal esophagectomy and lym-
phadenectomy via thoracoscopic surgery. We undergone 
reconstruction by stomach roll using subtotal stomach and 
hand-sewn anastomosis in cervical portion in all cases. All 
patients were considered to have achieved curative resec-
tion (R0).
Of the 32 patients who received surgery, postoperative 
complications (grade 2 or more according to NCI-CTCAE 
version 4.0) occurred in 3 patients in the form of grade 2 
recurrent nerve palsy and in 1 patient in the form of grade 2 
chylothorax. There were no anastomotic leakage and post-
operative deaths.
Treatment outcomes
Of all 32 patients, no patients failed to complete 2 courses 
of chemotherapy and no patients required a delay of chem-
otherapy during any of the courses for adverse events. No 
patients required a dose reduction in the all courses because 
grade 4 neutropenia occurred after the completion of the 2 
courses of the regimen.
All the patients received the surgery, and no patients 
required R1 resection pathologically. Thus, the completion 
rate (completion of 2 courses of preoperative chemotherapy 
and R0 surgery) of protocol treatment was 100 %.
Of the 31 patients who had measurable lesions, 6 
(19.4 %) had a complete response and 22 (71.0 %) had a 
partial response to therapy, resulting in an overall response 
rate of 90.3 % (95 % confidence interval 74.3–98.0 %) 
(Table 4).
The histological effects in the primary tumors were 
grade 3 in 7 (21.9 %) patients, grade 2 in 10 (31.3 %) 
patients, grade 1b in 3 (9.4 %) patients, and grade 1a in 12 
Table 1  Characteristics of patients
ECOG Eastern Cooperative Oncology Group, Ut upper thoracic 
esophagus, Mt middle thoracic esophagus, Lt lower thoracic esopha-
gus





 Males 26 81.3
 Females 6 18.8
ECOG performance status
 0–1 32 100
 2 0 0
Site of primary tumor
 Ut 8 25.0
 Mt 15 46.9
 Lt 9 28.1
Clinical T stage
 cT2 8 25.0
 cT3 24 75.0
Clinical N stage
 cN0 1 3.1
 cN1 9 28.1
 cN2 13 40.6
 cN3 9 28.1
Clinical stage
 IIB 3 9.4
 III 29 90.6
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(37.5 %) patients. The results also showed that 13 (41.9 %) 
of the 31 patients who were clinically diagnosed as posi-
tive for lymph node metastasis were pathologically node 
negative.
The median follow-up period was 30 months (range 
12–68 months). The 1-year RFS was 84.3 %. The 1-year 
survival rate was 90.6 %. The median RFS was not reached.
Discussion
Currently, additional treatments following surgery or radio-
therapy are necessary to improve long-term patient out-
come. In Western countries, neoadjuvant chemoradiother-
apy is a standard treatment for locally advanced esophageal 
cancer [10]. Meanwhile, in Japan, neoadjuvant chemother-
apy with FP has been approved as a standard regimen by 
the JCOG 9907 study [3]. There seemed to be a histologi-
cal difference in the background of esophageal cancer, and 
although FP was an effective regimen, the response rate of 
Table 2  Frequency of 
treatment-related toxicity
Data represent number of patients
CTCAE Common Terminology Criteria for Adverse Events of the National Cancer Institute
CTCAE version 4.0 common toxicity criteria
Grade 1 Grade 2 Grade 3 Grade 4 All grades (%) Grade 3/4 (%)
Hematological
 Leucopenia 5 12 4 0 21 (65.6) 4 (12.5)
 Neutropenia 2 7 8 2 19 (59.4) 10 (31.3)
 Febrile neutropenia – – 0 0 0 0
 Anemia 0 0 0 0 0 0
 Thrombocytopenia 0 1 0 0 1 (3.1) 0
Non-hematological
 Anorexia 8 5 0 0 13 (40.6) 0
 Fatigue 2 1 0 0 3 (9.4) 0
 Mucositis 2 9 0 0 11 (34.4) 0
 Nausea/vomiting 1 0 0 0 1 (3.1) 0
 Diarrhea 2 3 0 0 5 (15.6) 0
 Pericardial effusion – 0 0 0 0 0
 Alopecia 23 9 – – 32 (100) 0
 Edema 5 0 0 0 5 (15.6) 0
 Sensory neuropathy 0 0 0 0 0 0
 Dysgeusia 1 0 0 0 1 (3.1) 0
 Hyponatremia – – 0 0 0 0
Table 3  Operative details and postoperative outcomes
R0 no residual tumor, R1 suspicious of residual tumor or microscopic 
residual tumor
No of patients %
Surgical approach
 Right thoracotomy 30 93.8
 Thoracoscopic surgery 2 6.3
Type of resection
 R0 32 100
 R1 0 0
Postoperative complications
 Recurrent nerve palsy 3 9.4
 Pneumonia 0 0
 Anastomotic leakages 0 0
 Pyothorax 0 0
 Pneumothorax 0 0
 Chylothorax 1 3.1
 Wound infection 0 0
 Heart failure 0 0
 Postoperative mortality 0 0
Table 4  Overall response in this phase II trial
N = 31
Complete response 6 (19.4 %)
Partial response 22 (71.0 %)
Stable disease 3 (9.7 %)
Progressive disease 0
Overall response rate 90.3 %
Confidence interval 74.3–98.0
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38 % was unsatisfactory. Thus, a new regimen with low 
toxicity and high response is clearly desired.
In the present trial of Bi-DCF chemotherapy for esopha-
geal SCC, a combination regimen with DCF was shown to 
be highly tolerable and effective in patients with clinical 
stage II/III cancer in preoperative setting.
The taxanes enhance polymerization of tubulin into sta-
ble microtubule formations and inhibit their tubulin depo-
lymerization by blocking the cell cycle in metaphase, ana-
phase, and interphase [30]. This inhibition may improve 
the efficacy of drugs such as CDDP, which are active in 
all phases of the cell cycle via direct DNA damage. Fur-
thermore, the taxanes increase programmed cell death, and 
TXT appears to be more potent than paclitaxel in inhibiting 
angiogenesis [31].
TXT, CDDP, and 5-FU activity occurs by synergistic or 
non-cross-resistance effects when administered in combi-
nation [24]. Previously published studies have shown that 
the DCF combination has good efficacy [23, 32–38]. A 
34.5–83.3 % response rate was observed with DCF com-
binations used to treat patients with advanced esophageal 
carcinoma (Table 5).
We found that our Bi-DCF regimen also had a high 
response rate and showed highly promising antitumor 
activity. The histological grade 2/3 rate was 53.2 %, which 
is high compared with the 25–51 % reported previously 
[23, 36, 37]. The results emerging from this phase II study 
are particularly encouraging. By dividing the single dose 
of each of these three powerful drugs, it is not necessary 
to reduce their doses in the second course. Because this 
may eventually increase the dose intensity of the antitumor 
agent, it is likely that a high response rate can be obtained.
Previous studies indicated that this triplet regimen 
seems to be not inferior to chemoradiotherapy with respect 
to the local control rate [23, 39–41]. In the present study, 
24 (75.0 %) patients were clinically T3; remarkably, the 
histological effects regarding T3 tumor were grade 3 in 
7 (29.2 %), grade 2 in 8 (33.3 %), grade Ib in 1 (4.2 %), 
and grade Ia in 8 (33.3 %)patients. Therefore, this regimen 
might lead to more cases of locally highly advanced esoph-
ageal SCC.
Although TXT offers favorable outcomes, it causes 
adverse hematological toxicity. Because of high rate of 
blood toxicity resulting from the administration method 
used in previous reports, there appeared to be difficulties 
in enforcing the regimen in general hospitals. Neutropenia 
occurs approximately 8–10 days after TXT administration 
but recovers rapidly. TXT 75–100 mg/m2 every 3–4 weeks 
is associated with a quite pronounced neutropenia, up to 
44 % rate of febrile neutropenia in patients with recurrent 
ovarian cancer [42]. Several reports revealed that the major 
toxicity of DCF repeated every 3–4 weeks at doses of TXT 
50–75 mg/m2, CDDP60-75 mg/m2, and 5-FU 700–800 mg/
m2 was myelosuppression, and the frequencies of grade 
3/4 leucopenia and neutropenia in a phase II study were 
33.3 % and 90 %, respectively [23, 32–36], (Table 5). In 
our biweekly regimen, the incidence of hematological tox-
icity was lower than that in the other reports. Although we 
did not use a prophylactic antimicrobial agent, no febrile 
neutropenia occurred, and no thrombocytopenia ≥grade 3 
was observed.
To minimize toxicity and maximize the total dose 
intensity, we elected to investigate a biweekly regimen. 
Compared with the other DCF regimens for esophageal 
cancer of other phase I/II studies [23, 32–38], (Table 5), 
our regimen included a TXT dose intensity equivalent to 
the triweekly administration of TXT performed in those 
studies. Divided administration of TXT and CDDP may 
reduce myelosuppression and neuropathy while maintain-
ing almost unchanged efficacy. Tebbutt et al. [24] showed 
that weekly TXT administration in the triplet DCF regimen 
reduced blood toxicity for patients with esophagogastric 
cancer.
In the present phase II trial, the incidence of TXT-spe-
cific toxicities, such as neurotoxicity and acute hyper-
sensitivity reactions [22], was relatively low and did not 
appear to be a major clinical problem, so a reduction in 
dose generally was not required. This was probably due 
to the low per-day dose of TXT administered via the 
biweekly method. Fluid retention manifesting as periph-
eral edema, pleural effusion, or ascites was cumulative 
in incidence and severity, but no patient had severe body 
weight gain that required diuretics. Patients receiving 
more than 50 mg/m2 of CDDP may suffer nausea and 
vomiting [43]. Both are frequent side effects and can 
be well controlled by biweekly method and the admin-
istration of granisetron and dexamethasone. Thus, non-
hematological toxicity was comparable to that of other 
reports.
The Bi-DCF regimen seemed to be useful as preop-
erative chemotherapy due to the small need to delay the 
anticancer drug administration schedule, and it did not 
adversely affect our elective surgery schedule. In fact, sur-
gery was carried out according to plan in all 32 patients, 
and no surgeries were delayed. Moreover, there was no 
mortality, and no serious postoperative complications 
occurred.
In conclusion, the preoperative Bi-DCF regimen was 
well tolerated and useful for the treatment of resectable 
esophageal SCC. It could potentially be offered as a can-
didate component of standard regimens for treating resect-
able esophageal SCC. A further phase III clinical trial using 
this triplet combination should be pursued in the treatment 
of advanced esophageal SCC.
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